Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis

Cytokine Growth Factor Rev. 2022 Jun:65:12-26. doi: 10.1016/j.cytogfr.2022.04.007. Epub 2022 May 9.

Abstract

Atopic dermatitis is a chronic recurring pruritic inflammatory skin disease manifested by increased pro-inflammatory mediators which lead to dry, thickened, cracked, scaly skin. The current treatment options for atopic dermatitis management comprise drawbacks and leave unmet effective clinical needs. So, the approach for repurposing existing drugs for atopic dermatitis management may potentially overcome these unmet needs. Diseases that share the common pathophysiological pathways with atopic dermatitis can serve as a foundation for the repurposing of drugs. Drugs used in the management of cancer, rheumatoid arthritis, and other immune-mediated diseases such as psoriasis are under investigation to know the potential in atopic dermatitis management by utilizing repurposing strategies for a novel therapeutic indication. This review mainly envisages the probable repurposing of drugs for the management of atopic dermatitis disease; the barriers and regulatory aspects involved in the repurposing of existing drugs.

Keywords: Atopic dermatitis; Drug repurposing; Inflammation; JAK inhibitors; PDE-4 inhibitors; regulatory considerations.

Publication types

  • Review

MeSH terms

  • Dermatitis, Atopic* / drug therapy
  • Drug Repositioning
  • Humans
  • Psoriasis*
  • Skin